The purpose of this study is to learn more about what psychological and social factors affect people in how they take their hepatitis C medications.
The goal of this study is to determine if a qualitative survey that assesses a patient's readiness for treatment of Hepatitis C (HCV) and associated interventions based on identified barriers can improve treatment adherence and outcomes. HCV remains a leading cause of liver cancer and end stage liver disease despite greater than 90% cure rates with new, all-oral antiviral medications. While these new medications are easier to tolerate and access than previous treatment regimens, medication adherence still remains a great barrier to cure. In this study, we will administer the Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool, a free, online survey developed at the Mount Sinai School of Medicine to determine psychosocial readiness for treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
100
The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool assesses a patient's psychosocial readiness to start HCV treatment. There are nine sections in the survey: 1. Motivation: reasons client wants to begin HCV treatment, concerns about treatment, and the importance of treatment 2. Information: knowledge about HCV treatment and one's own HCV disease status 3. Medication Adherence: current prescribed medications and adherence to them in the prior month 4. Self-efficacy: self-confidence about adhering to HCV treatment 5. Social Support and Stability: stability of financial, housing, and social support resources 6. Alcohol and substance use: alcohol and substance use behaviors and current treatment 7. Psychiatric Stability: current psychiatric status, previous and current treatment 8. Energy Level: sleep and fatigue 9. Cognitive Functioning: perceived difficulty with communication in health care setting, problem-solving ability, and memory.
Grady Liver Clinic
Atlanta, Georgia, United States
Number of participants keeping follow-up appointments
Adherence to HCV treatment will be measured by documenting the number of participants keeping their follow-up appointments. This data will be collected from chart reviews.
Time frame: At 4 months
Number of participants keeping follow-up appointments
Adherence to HCV treatment will be measured by documenting the number of participants keeping their follow-up appointments. This data will be collected from chart reviews.
Time frame: At 8 months
Number of participants refilling medications
Adherence to HCV treatment will be measured by documenting the number of participants who refill their medications. This data will be collected from chart reviews.
Time frame: At 4 months
Number of participants refilling medications
Adherence to HCV treatment will be measured by documenting the number of participants who refill their medications. This data will be collected from chart reviews.
Time frame: At 8 months
Number of participants who keep lab visits
Adherence to HCV treatment will be measured by documenting the number of participants who keep their lab visits.This data will be collected from chart reviews.
Time frame: At 4 months
Number of participants who keep lab visits
Adherence to HCV treatment will be measured by documenting the number of participants who keep their lab visits.This data will be collected from chart reviews.
Time frame: At 8 months
Rapid virologic response (RVR)
The treatment outcome will be measured by analyzing the rapid virologic response (RVR) at 4 weeks after completion of treatment. Rapid virologic response (RVR) is defined as an undetectable serum hepatitis C virus (HCV) RNA. This data will be collected from chart reviews.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: At 4 weeks
Sustained virologic response (SVR)
The treatment outcome will be measured by analyzing the sustained virologic response (SVR) at 12 weeks after completion of treatment. SVR is defined as aviremia 12 weeks after completion of antiviral therapy. This data will be collected from chart reviews.
Time frame: At 12 weeks